QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:ALLK

Allakos (ALLK) Stock Forecast, Price & News

$4.94
-0.19 (-3.70%)
(As of 06/6/2023 ET)
Compare
Today's Range
$4.92
$5.15
50-Day Range
$3.60
$5.25
52-Week Range
$2.54
$8.73
Volume
855,264 shs
Average Volume
1.03 million shs
Market Capitalization
$427.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.60

Allakos MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
175.3% Upside
$13.60 Price Target
Short Interest
Healthy
8.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.72mentions of Allakos in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.99) to ($1.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

85th out of 981 stocks

Pharmaceutical Preparations Industry

30th out of 464 stocks


ALLK stock logo

About Allakos (NASDAQ:ALLK) Stock

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Jefferies Upgrades Allakos (ALLK)
Analyst Ratings for Allakos
Allakos: Q1 Earnings Insights
LifeSci Capital Keeps Their Buy Rating on Allakos (ALLK)
Allakos Inc. (NASDAQ:ALLK) Short Interest Update
Where Allakos Stands With Analysts
Why Allakos Stock Was Heating Up Today
See More Headlines

ALLK Price History

ALLK Company Calendar

Last Earnings
5/09/2023
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.60
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+173.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-319,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.64 per share

Miscellaneous

Free Float
57,779,000
Market Cap
$431.07 million
Optionable
Not Optionable
Beta
0.44

Key Executives

  • Robert AlexanderRobert Alexander
    Chief Executive Officer & Director
  • Adam L. Tomasi
    President
  • Harlan Baird Radford
    Chief Financial Officer
  • Craig Paterson
    Chief Medical Officer
  • Brad Youngblood
    Head-Research & Pre-Clinical Development













ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALLK shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price forecast for 2023?

6 Wall Street analysts have issued 12-month target prices for Allakos' stock. Their ALLK share price forecasts range from $7.00 to $22.00. On average, they predict the company's share price to reach $13.60 in the next year. This suggests a possible upside of 173.1% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2023?

Allakos' stock was trading at $8.42 at the beginning of 2023. Since then, ALLK stock has decreased by 40.9% and is now trading at $4.98.
View the best growth stocks for 2023 here
.

Are investors shorting Allakos?

Allakos saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, a drop of 12.6% from the April 30th total of 4,930,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is presently 3.7 days. Currently, 8.3% of the shares of the company are sold short.
View Allakos' Short Interest
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49).

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (7.00%), Logos Global Management LP (6.40%), State Street Corp (4.42%), BlackRock Inc. (2.95%), Commodore Capital LP (2.20%) and Federated Hermes Inc. (1.76%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $4.98.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $431.07 million. The company earns $-319,950,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Allakos have?

The company employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -